Search clinical trials for: Fluticasone Propionate 500mcg

Total 2959 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
GlaxoSmithKline

Completed

A Healthy Volunteer Study With Inhaled GSK573719 and Placebo

Pulmonary Disease, Chronic Obstructive

Belgium
GlaxoSmithKline

Completed

GSK BHR Study (Sont - Second Study)

Asthma

United States, Bulgaria, Puerto Rico, Brazil
GlaxoSmithKline

Completed

GSK BHR Study (Sont)

Asthma

United States, Latvia, Puerto Rico, Brazil
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Inmagene LLC

Completed

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
GlaxoSmithKline

Completed

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Asthma

Russian Federation, United States, Peru, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Sandoz

Completed

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Asthma

United States
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Australia, Germany, Russian Federation, Bulgaria, Canada, Chile, Peru, Philippines, South Africa, Thailand, Mexico, Israel, Ukraine, New Zealand, Croatia
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (QvarAsthma)

Asthma

United Kingdom
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
GlaxoSmithKline
Parexel

Completed

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

Asthma

United States, Australia, Poland, Russian Federation, Spain, Ukraine, Germany, Bulgaria, Argentina, Peru, South Africa, Taiwan, Belgium, Italy, Hungary, Korea, Republic of, Austria, Romania, Colombia, Slovakia, United Kingdom, Mexico and more
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, United States, Czechia, Russian Federation
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... and other collaborators

Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)

Neutropenia

China
University of Florida
Food and Drug Administration (FDA)

Completed

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution

Asthma

United States
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Asthma

Germany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
GlaxoSmithKline

Completed

Fluticasone Nasal Spray Patient Preference Study

Rhinitis, Allergic, Perennial

United States
Phloronol Inc.
Worldwide Clinical Trials

Completed

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

Safety Issues

United States
GlaxoSmithKline

Completed

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Asthma

United States, Japan, Romania, Ukraine, Bulgaria, Poland
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline

Completed

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Asthma

United States, Argentina, Germany, Japan, Chile, Peru, Philippines, Poland, Mexico, Slovakia, Ukraine, South Africa, Puerto Rico, Georgia
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Diabetic Neuropathies

Korea, Republic of
Medicines for Malaria Venture

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

Healthy Volunteers | Malaria Falciparum | Malaria Vivax

United States
GlaxoSmithKline
Parexel

Completed

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI)

Asthma

United States, Australia, Spain, Taiwan, Bulgaria, Russian Federation, Ukraine, Argentina, Germany, Peru, Poland, South Africa, Thailand, Korea, Republic of, Austria, Belgium, Hungary, Italy, Slovakia, Malaysia, Czechia, Mexico, United... and more
Yuhan Corporation

Completed

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Imperial College London

Completed

Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate

Healthy | Asthma

United Kingdom
GlaxoSmithKline

Completed

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Netherlands
Teva Pharmaceuticals USA

Terminated

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

United States
Pfizer

Completed

A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Genzyme, a Sanofi Company

Completed

ZD6474 Phase IIa Dose Finding Multicentre Study

Non Small Cell Lung Carcinoma

Japan
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

Healthy

China
GlaxoSmithKline

Completed

Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.

Asthma

United Kingdom, Belgium
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
Padagis LLC

Completed

Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments

Healthy
GlaxoSmithKline

Completed

An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
Boehringer Ingelheim

Completed

BI 671800 ED in Steroid-naive Asthmatic Patients

Asthma

United States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan

Search clinical trials for: Fluticasone Propionate 500mcg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations